Fairvalue-Calculator Fairvalue-Calculator
EN DE

GC Cell Corporation (144510) Fair Value & Analysis

Healthcare · KR · Market cap 261B KRW

Price15,030 KRW
Fair Value22,327 KRW
Upside+48.5%
Quality93/100
Evidence: Medium Range 16,745 KRW – 27,908 KRW

Fair value as of: Jun 24, 2026

Analysis

GC Cell Corporation (144510) currently trades at 15,030 KRW, while our model-based Fair Value estimate is 22,327 KRW — implying the stock looks roughly 48.5% undervalued today. We read business quality at 93/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

GC Cell Corporation develops cell therapy products. It also provides cell banking, sample inspection, clinical trial, and bio logistics services. Its main product is Immuncell-LC. GC Cell Corporation has strategic agreement with Lukas Biomedical Co., Ltd. to develop Cell therapy. The company was formerly known as Green Cross Lab Cell Corporation and changed its name to GC Cell Corporation in November 2021. GC Cell Corporation was founded in 2011 and is based in Yongin-si, South Korea.

Open the full interactive analysis →

Similar stocks

Thermo Fisher Scientific Inc (TMO) -96% Danaher Corporation (DHR) -52% WuXi AppTec Co (WUXAY) +35% IDEXX Laboratories, Inc (IDXX) -66% Lonza Group (LZAGY) -77% Agilent Technologies, Inc (A) -54%

Frequently asked questions

Is GC Cell Corporation (144510) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 22,327 KRW versus a price of 15,030 KRW — about +49% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 144510?
Our 21-model fair value for GC Cell Corporation is 22,327 KRW (as of Jun 24, 2026), built from audited fundamentals. The current price is 15,030 KRW.
What is the quality score of 144510?
GC Cell Corporation has a Quality Score of 93/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.